In this paper we review some of the preclinical findings which have led us to believe that immunotherapy with interleukin 2 (IL2)/lymphokine activated killer (LAK) cells may be a feasible approach in the management of acute myeloid leukemia. The main clinical and biological results so far obtained with IL2 treatment, and the currently ongoing protocols and strategies are discussed
Interleukin 2 in the management of hematologic malignancies / Foa, Roberto; Meloni, Giovanna; Guarini, Anna; Vignetti, Marco; Mandelli, Franco; F., Gavosto. - In: PHARMACOLOGICAL RESEARCH. - ISSN 1043-6618. - STAMPA. - 26 Suppl 2:(1992), pp. 115S-116S.
Interleukin 2 in the management of hematologic malignancies.
FOA, Roberto;MELONI, Giovanna;GUARINI, Anna;VIGNETTI, Marco;MANDELLI, Franco;
1992
Abstract
In this paper we review some of the preclinical findings which have led us to believe that immunotherapy with interleukin 2 (IL2)/lymphokine activated killer (LAK) cells may be a feasible approach in the management of acute myeloid leukemia. The main clinical and biological results so far obtained with IL2 treatment, and the currently ongoing protocols and strategies are discussedFile allegati a questo prodotto
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
